复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

未开盘 02-12 16:08:09

20.760

-0.380

-1.80%

最高21.520	最低20.760	成交量215.68万
今开21.120	昨收21.140	日振幅3.60%
总市值552.01亿	流通市值112.31亿	总股本26.59亿
成交额4,503万	换手率0.40%	流通股本5.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":20.76,"timestamp":1770883689003,"preClose":21.14,"halted":0,"volume":2156790,"delay":0,"changeRate":-0.0179754020813623,"floatShares":540971500,"shares":2659000000,"eps":1.037252,"marketStatus":"未开盘","change":-0.38,"latestTime":"02-12 16:08:09","open":21.12,"high":21.52,"low":20.76,"amount":45029069,"amplitude":0.035951,"askPrice":20.82,"askSize":1000,"bidPrice":20.76,"bidSize":58500,"shortable":3,"etf":0,"ttmEps":1.352842,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770946200000},"marketStatusCode":0,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":21.14,"dividendRate":0.017325,"openAndCloseTimeList":[[1770859800000,1770868800000],[1770872400000,1770883200000]],"volumeRatio":0.8401929803891489,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":26.87,"timestamp":1770879600000,"preClose":27.23,"halted":0,"volume":12354900,"delay":0,"premium":"-31.81"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2611976680","title":"复星医药控股子公司药品获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2611976680","media":"格隆汇资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611976680?lang=zh_cn&edition=full","pubTime":"2026-02-12 17:54","pubTimestamp":1770890043,"startTime":"0","endTime":"0","summary":"格隆汇2月12日丨复星医药公告，近日，上海复星医药(集团)股份有限公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司收到国家药品监督管理局关于同意HLX15-SC用于多发性骨髓瘤治疗开展Ⅰ期临床试验的批准。复宏汉霖拟于条件具备后在中国境内开展该药品的相关临床研究。2024年6月，在中国男性健康受试者中开展的HLX15-IVⅠ期临床研究已完成。根据IQVIAMIDAS1最新数据，2024年，达雷妥尤单抗制剂于全球范围的销售额约128.82亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212175415a6f2df4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212175415a6f2df4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02196","HK0000165453.HKD","02696","BK1161","HK0000306701.USD","HK0000306685.HKD","HK0000320264.USD","BK1515","HK0000320223.HKD","BK1593"],"gpt_icon":0},{"id":"2610009929","title":"每日卖空追踪 | 复星医药 02月12日卖空量成交10.85万股，卖空比例为5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610009929","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610009929?lang=zh_cn&edition=full","pubTime":"2026-02-12 16:30","pubTimestamp":1770885028,"startTime":"0","endTime":"0","summary":"复星医药北京时间02月12日，跌1.8%，卖空量成交10.85万股，较上一交易日增加171.25%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212163353a49b9f44&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212163353a49b9f44&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1191","02196","BK1515"],"gpt_icon":0},{"id":"2610929004","title":"复星医药02月12日主力净流出467.1万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2610929004","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610929004?lang=zh_cn&edition=full","pubTime":"2026-02-12 16:15","pubTimestamp":1770884129,"startTime":"0","endTime":"0","summary":"02月12日, 复星医药股价跌1.80%，报收20.76元，成交金额4502.9万元，换手率0.40%，振幅3.60%，量比0.84。复星医药今日主力资金净流出467.1万元，上一交易日主力净流入64.5万元。该股近5个交易日下跌0.10%，主力资金累计净流出787.0万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出2698.1万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212161708a49b8be4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212161708a49b8be4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02196","BK1593","BK1515"],"gpt_icon":0},{"id":"2610693091","title":"复星医药：公司始终坚持创新驱动发展战略，持续聚焦创新药品和高端器械","url":"https://stock-news.laohu8.com/highlight/detail?id=2610693091","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610693091?lang=zh_cn&edition=full","pubTime":"2026-02-11 21:05","pubTimestamp":1770815108,"startTime":"0","endTime":"0","summary":"证券日报网讯2月11日，复星医药在互动平台回答投资者提问时表示，公司始终坚持创新驱动发展战略，持续聚焦创新药品和高端器械，并通过不断深化精益运营、持续完善市值管理体系、优化市场沟通机制，推动市场价值与企业内在价值相匹配。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602113648144667.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0187","BK0239","BK1191","BK0183","BK0196","02196","BK0096","BK0012","600196","BK0175","BK0060","BK1593","BK0188","BK0028","BK1515"],"gpt_icon":0},{"id":"2610803869","title":"复星医药：上市公司为控股子公司复星健康提供2000万元担保，复星诊断为复星诊断长沙提供不超过2500万元担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2610803869","media":"公司公告","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610803869?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:45","pubTimestamp":1770799517,"startTime":"0","endTime":"0","summary":"复星医药 公告，上市公司为控股子公司复星健康提供人民币2000万元担保，复星诊断为其控股子公司复星诊断长沙提供不超过2500万元担保。本次担保均在前期预计额度内，部分被担保方资产负债率超过70%。截至2026年2月11日，公司及控股子公司对外担保总额折合人民币约227.583亿元，占2024年12月31日经审计净资产的48.15%，无逾期担保事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211164947a4974329&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211164947a4974329&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02196","BK1515","BK1593"],"gpt_icon":0},{"id":"2610980355","title":"华阳智能：复星惟盈累计减持0.95%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2610980355","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610980355?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:39","pubTimestamp":1770799185,"startTime":"0","endTime":"0","summary":"格隆汇2月11日丨华阳智能(301502.SZ)公布，公司收到复星惟盈出具的《关于减持公司股份减持比例触及1%整数倍的告知函》，复星惟盈在2026年1月22日至2026年2月9日期间内以集中竞价和大宗交易方式累计减持公司股份54万股，占公司总股本的0.95%。本次权益变动后，复星惟盈持股占公司总股本比例由11.92%变动为10.98%，权益变动触及1%的整数倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211164004a6ee2560&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211164004a6ee2560&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1191","BK1515","02196"],"gpt_icon":0},{"id":"2610787648","title":"2月10日复星医药现695.41万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2610787648","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610787648?lang=zh_cn&edition=full","pubTime":"2026-02-10 17:27","pubTimestamp":1770715662,"startTime":"0","endTime":"0","summary":"证券之星消息，2月10日复星医药发生大宗交易，交易数据如下：大宗交易成交价格27.08元，成交25.68万股，成交金额695.41万元，买方营业部为国泰海通证券股份有限公司总部，卖方营业部为国泰海通证券股份有限公司总部。近三个月该股共发生2笔大宗交易，合计成交5668.0手，折价成交1笔。截至2026年2月10日收盘，复星医药报收于27.08元，上涨0.97%，换手率0.72%，成交量15.34万手，成交额4.15亿元。该股最近90天内共有1家机构给出评级，买入评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000028174.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600196","BK0028","BK1593","BK0060","02196","BK1191","BK0183","BK1515","BK0187","BK0175","BK0188","BK0196","BK0012","BK0096","BK0239"],"gpt_icon":0},{"id":"2610610481","title":"复星医药的“腾笼换鸟”：出清、收购、分拆","url":"https://stock-news.laohu8.com/highlight/detail?id=2610610481","media":"蓝鲸财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610610481?lang=zh_cn&edition=full","pubTime":"2026-02-10 17:04","pubTimestamp":1770714293,"startTime":"0","endTime":"0","summary":"不得不改变复星医药分拆上市的路径，颇值得玩味。资本运作的两个核心复星医药的“钢丝”，已显而易见。分拆上市的同日，公司公告大股东复星高科技新质押所持股份，用以偿还债务。公司左手出清非核心资产、分拆上市，右手高溢价收购，复杂程度让市场困惑。其实，从出清到收购再到分拆，本质是公司在布局一场精心计算过的“腾笼换鸟”：出清、分拆前景不明的资产换回现金，再逐步拿下绿谷医药的核心资产兑现商业化潜力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1770687870559158944","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0183","BK0012","BK0188","BK0196","BK0239","BK1593","BK0175","BK0060","600196","BK0187","02196","BK1191","BK1515","BK0096","BK0028"],"gpt_icon":0},{"id":"2610617153","title":"复星医药子公司盐酸丁卡因凝胶注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2610617153","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610617153?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:42","pubTimestamp":1770712975,"startTime":"0","endTime":"0","summary":"2月10日，复星医药（600196/02196）发布公告，控股子公司药品注册申请获国家药品监督管理局受理。此次申请涉及盐酸丁卡因凝胶，该药品为集团自主研发的化学药品，拟用于经皮局部麻醉，适用于成人及1个月以上的婴儿。至2025年12月，集团针对该药品的累计研发投入约为719万元（未经审计）。根据IQVIACHPA最新数据，2024年该药品在中国境内的销售额约为4.43亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602103646706489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK1515","BK0183","BK0012","BK0175","02196","BK0196","BK0239","600196","BK1191","BK0028","BK0096","BK0187","BK1593","BK0060"],"gpt_icon":0},{"id":"2610610313","title":"每日卖空追踪 | 复星医药 02月10日卖空量成交33.3万股，卖空比例为8.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610610313","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610610313?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:30","pubTimestamp":1770712230,"startTime":"0","endTime":"0","summary":"复星医药北京时间02月10日，涨2.02%，卖空量成交33.3万股，较上一交易日增加145.76%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210163353a6e9ad4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210163353a6e9ad4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1593","BK1515","02196"],"gpt_icon":0},{"id":"2610969486","title":"创新药概念震荡反弹 高增长潜力概念股出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=2610969486","media":"腾讯自选股综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610969486?lang=zh_cn&edition=full","pubTime":"2026-02-10 11:17","pubTimestamp":1770693474,"startTime":"0","endTime":"0","summary":"创新药概念盘中震荡反弹，广生堂涨超10%，此前万邦德涨停，尖峰集团、信立泰、北陆药业、荣昌生物、首药控股等多股涨超5%。华源证券指出，经历短期波动消化后，创新药板块已显现企稳回暖迹象。整体上，国金证券认为创新药前期回调较为充分，向上产业趋势明确，催化近期密集，继续看好板块投资机会。从未来增长潜力来看，多股获机构预测2026年净利增速有望翻倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021010545497a590eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021010545497a590eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","01548","00013","06185","00867","02228","03692","01801","02269","06160","01877","02196","BK1574","00512","01952","01093","06978","BK1515","01513","01177","BK1583","BK1161","02096"],"gpt_icon":0},{"id":"2609452564","title":"每周股票复盘：复星医药（600196）发行10亿科技创新债券","url":"https://stock-news.laohu8.com/highlight/detail?id=2609452564","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609452564?lang=zh_cn&edition=full","pubTime":"2026-02-08 01:56","pubTimestamp":1770486973,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，复星医药报收于26.68元，较上周的26.67元上涨0.04%。本周，复星医药2月5日盘中最高价报26.8元。本周关注点公司公告汇总：复星医药完成发行10亿元科技创新债券，期限2年，利率2.40%。控股子公司复星医药产业自主研发的芦沃美替尼片（复迈宁）用于治疗Ⅰ型神经纤维瘤病成人患者的新增适应症，其上市申请已获国家药监局受理并纳入优先审评程序。截至2025年12月累计研发投入约6.63亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0096","BK0175","BK0183","BK1191","600196","BK1593","BK0012","BK0187","BK0239","BK0188","BK0028","BK0060","BK0196","02196"],"gpt_icon":0},{"id":"2609206403","title":"复星医药(02196)：环磷酰胺注射液的药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2609206403","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609206403?lang=zh_cn&edition=full","pubTime":"2026-02-05 17:27","pubTimestamp":1770283627,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)公布，近日，公司控股子公司吉斯美(武汉)制药有限公司就环磷酰胺注射液的药品注册申请获国家药品监督管理局受理。据悉，该药品为集团自主研发的化学药品，拟用于治疗患有以下疾病的成人和儿童患者：恶性淋巴瘤、霍奇金病、淋巴细胞性淋巴瘤、混合细胞型淋巴瘤、组织细胞性淋巴瘤、伯基特淋巴瘤、多发性骨髓瘤、白血病、蕈样肉芽肿、神经母细胞瘤、卵巢腺癌、视网膜母细胞瘤、乳腺癌。截至 2025 年 12 月，集团现阶段针对该药品的累计研发投入约为人民币 740 万元(未经审计)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","600196","BK0183","BK0012","02196","BK0175","BK0187","BK1515","BK1593","BK0028","BK0096","BK0188","BK1191","BK0060","BK0196"],"gpt_icon":0},{"id":"2609322049","title":"复星医药(600196.SH)控股子公司复宏汉霖与Eisai签订许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2609322049","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609322049?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:46","pubTimestamp":1770281167,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，2026年2月5日，公司控股子公司复宏汉霖与Eisai签订《许可协议》，由复宏汉霖授予Eisai于许可区域(即日本)及领域开发、生产及商业化斯鲁利单抗注射液的权利。基于许可产品于许可区域的年度净销售额达成情况，Eisai应依约向复宏汉霖支付至多23,333万美元的销售里程碑款项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","HK0000306685.HKD","HK0000320264.USD","600196","BK0096","BK0187","HK0000320223.HKD","BK0183","HK0000165453.HKD","BK0175","02196","BK0239","BK1191","BK1515","BK0028","BK1593","BK0060","BK0196","HK0000306701.USD","BK0188","BK0012","BK1161"],"gpt_icon":0},{"id":"2609432214","title":"复星医药：复迈宁新适应症上市申请获优先审评受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2609432214","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609432214?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:43","pubTimestamp":1770280995,"startTime":"0","endTime":"0","summary":"2月5日，复星医药（600196/02196）发布公告，控股子公司药品注册申请获受理。公司控股子公司上海复星医药产业发展有限公司自主研发的复迈宁?（通用名：芦沃美替尼片）用于治疗伴有症状、无法手术的丛状神经纤维瘤的Ⅰ型神经纤维瘤病成人患者的药品上市申请已获国家药品监督管理局受理，并被纳入优先审评程序。截至2025年12月，针对该药品的累计研发投入约为6.63亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602053642780133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK0187","BK1593","02196","BK0188","BK0096","BK0183","600196","BK0196","BK0012","BK0028","BK1191","BK1515","BK0175","BK0060"],"gpt_icon":0},{"id":"2609309515","title":"每日卖空追踪 | 复星医药 02月05日卖空量成交3.45万股，卖空比例为1.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609309515","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609309515?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:30","pubTimestamp":1770280228,"startTime":"0","endTime":"0","summary":"复星医药北京时间02月05日，涨0.98%，卖空量成交3.45万股，较上一交易日减少31.68%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205163518a6d65636&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205163518a6d65636&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1191","BK1515","BK1593"],"gpt_icon":0},{"id":"2609131245","title":"两会对话｜复星医药文德镛：商保创新药目录落地仍需突破三个瓶颈","url":"https://stock-news.laohu8.com/highlight/detail?id=2609131245","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609131245?lang=zh_cn&edition=full","pubTime":"2026-02-05 07:56","pubTimestamp":1770249406,"startTime":"0","endTime":"0","summary":"“尽管政策取得积极进展，但商保创新药目录的落地和实施仍存在困难。”2月3日，上海市人大代表、复星医药副董事长文德镛在接受澎湃新闻记者独家专访时表达了上述观点。公开数据显示，当前创新药销售费用构成中，基本医疗保险承担44%，商业保险仅承担7%，剩余近半数费用需通过患者自费或其他渠道解决，商保保障效能尚未充分释放。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602053642106781.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602053642106781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK0175","BK0096","BK1574","BK1161","159992","BK0060","BK0187","BK0188","600196","BK1515","BK0239","BK1593","02196","BK0183","BK0196","BK0012","BK0028","BK1191"],"gpt_icon":0},{"id":"2608398235","title":"复星医药（600196）披露拟分拆子公司复星安特金赴港上市，2月4日股价上涨1.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608398235","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608398235?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:39","pubTimestamp":1770215954,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘，复星医药报收于26.64元，较前一交易日上涨1.14%，最新总市值为711.4亿元。该股当日开盘26.35元，最高26.64元，最低26.12元，成交额达3.84亿元，换手率为0.69%。近日，上海复星医药（集团）股份有限公司披露拟分拆所属子公司复星安特金至香港联交所主板上市。公司董事会已审议通过相关议案，提请股东大会审议分拆方案及相关事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400041766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","600196","BK1593","BK0196","BK0060","BK0187","02196","BK1515","BK0175","BK0183","BK0188","BK0239","BK0028","BK0012","BK1191"],"gpt_icon":0},{"id":"2608362077","title":"复星医药：公司直接运营的业务覆盖制药、医疗器械及医学诊断、医疗健康服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2608362077","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608362077?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:37","pubTimestamp":1770212245,"startTime":"0","endTime":"0","summary":"证券日报网讯2月4日，复星医药在互动平台回答投资者提问时表示，公司自1994年创立于上海，是一家植根中国、创新驱动的全球化医药健康产业集团。目前，公司直接运营的业务覆盖制药、医疗器械及医学诊断、医疗健康服务；其中，制药是公司的核心主营业务，也是公司品牌建设的重要承载。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602043641720167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09997","BK1100","BK4581","LABU","159760","BK4585","BK0096","BK0196","BK1515","BK0028","BK0183","BK1593","BK0060","BK0239","BK0175","BK0012","BK4588","BK1583","BK0187","159883","09996","BK1574","02196","XLV","BK1222","BK1191","XBI","01477","600196","BK0188"],"gpt_icon":0},{"id":"2608420332","title":"1月5个创新药纳入优先审评品种名单，来自武田、复星医药等","url":"https://stock-news.laohu8.com/highlight/detail?id=2608420332","media":"制药网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608420332?lang=zh_cn&edition=full","pubTime":"2026-02-04 10:32","pubTimestamp":1770172329,"startTime":"0","endTime":"0","summary":"回顾刚刚过去的1月，多款创新药纳入优先审评，包括武田的奥博雷通片、德镁医药的磷酸芦可替尼乳膏、复星医药的芦沃美替尼片、和黄医药的醋酸索乐匹尼布片、同源康医药的甲磺酸艾多替尼片等。2026年1月多款创新药集中纳入优先审评，涵盖罕见病、皮肤疾病、肿瘤、肺癌等多个治疗领域，这些创新药被纳入优先评审，标志着审评进程将全面提速，有望更早上市，为中国患者提供新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204103636a6d0c77f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204103636a6d0c77f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06978","BK1161","02196","BK1191","BK1515","BK1593"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":0.0117},{"period":"1month","weight":-0.0503},{"period":"3month","weight":-0.1029},{"period":"6month","weight":-0.0433},{"period":"1year","weight":0.4301},{"period":"ytd","weight":0.0619}],"compareEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":0.0069},{"period":"3month","weight":-0.0015},{"period":"6month","weight":0.0697},{"period":"1year","weight":0.2367},{"period":"ytd","weight":0.0547}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044492},{"month":2,"riseRate":0.785714,"avgChangeRate":0.038766},{"month":3,"riseRate":0.615385,"avgChangeRate":0.048431},{"month":4,"riseRate":0.384615,"avgChangeRate":0.03076},{"month":5,"riseRate":0.461538,"avgChangeRate":0.035265},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.026545},{"month":7,"riseRate":0.615385,"avgChangeRate":0.027595},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.041651},{"month":9,"riseRate":0.461538,"avgChangeRate":0.011609},{"month":10,"riseRate":0.461538,"avgChangeRate":0.020359},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034495},{"month":12,"riseRate":0.428571,"avgChangeRate":0.015123}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}